Evidence map›Paper›PMID 40814874›Full record

ReviewCurrent pharmaceutical design2026

Exploring the Neurobiological Mechanisms of Cancer Growth.

Md Sadique Hussain, Mudasir Maqbool, Mohit Agrawal, Amita Joshi Rana, Ayesha Sultana, Nasreen Sulthana, Ajay Singh Bisht, Gyas Khan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Md Sadique HussainUttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Prem Nagar, Dehradun, 248007, Uttarakhand, India.ORCID 0000-0002-3554-1750
Mudasir MaqboolDepartment of Pharmaceutical Sciences, University of Kashmir, Hazratbal, Srinagar, 190006, Jammu and Kashmir, India.ORCID 0000-0002-9036-008X
Mohit AgrawalDepartment of Pharmacology, School of Medical & Allied Sciences, K.R. Mangalam University, Gurugram, 122103, India.ORCID 0000-0003-0200-7882
Amita Joshi RanaCollege of Pharmacy, Graphic Era Hill University, Bhimtal, 263136, Uttarakhand, India.ORCID 0000-0003-1907-4459
Ayesha SultanaDepartment of Pharmaceutics, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to be University), Mangalore, Karnataka, India.ORCID 0000-0003-3773-6604
Nasreen SulthanaDepartment of Pharmacology, Sree Dattha Institute of Pharmacy, Sheriguda, Hyderabad, 501510, Telangana, India.
Ajay Singh BishtSchool of Pharmaceutical Sciences, Shri Guru Ram Rai University, Patel Nagar, Dehradun, 248001, Uttarakhand, India.ORCID 0000-0002-2702-1827
Gyas KhanDepartment of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.ORCID 0000-0003-2695-7401

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging evidence reveals that interactions between the nervous system and tumor biology significantly influence cancer progression, metastasis, and therapeutic outcomes. Here, we elucidate the neurobiological mechanisms that underpin tumor development, highlighting the dynamic role of neural components within the tumor microenvironment (TME). Neural signals and structural adaptations in the TME stimulate tumorigenesis and enable cancer cell plasticity, mimicking neurodevelopmental processes. Astrocytic glial cells release neurotrophic factors that support metastatic colonization and enhance tumor cell survival. Notably, cancer cells can establish pseudo-tripartite synapses with neurons, promoting both proliferation and invasion. We explore the cancer-neural network interplay, emphasizing how axonal remodeling, circuit reorganization, and synaptic dysfunction not only drive tumor growth but also contribute to associated symptoms like seizures and chronic pain. Molecularly, mutations such as in PIK3CA and abnormalities in neurotransmitter signaling reveal how neurotumors communicate and adapt. Furthermore, metabolic stress responses from tumor cells can activate nociceptive neurons, sustaining malignant progression. Understanding these neurobiological interactions opens avenues for novel therapeutic strategies. Precision neuro-oncology may benefit from targeting neurotrophic signaling, synaptic pathways, and neuronal differentiation programs. Advances in biomarker research from neurotumors also contribute to improved diagnostic and prognostic tools. By integrating neuroscience insights into oncological frameworks, we propose a paradigm shift toward therapies that intercept the neural circuitry sustaining malignancies. This neuro-oncological approach holds promise in addressing aggressive cancer phenotypes and improving patient outcomes.

Indexed as

NeoplasmsAnimalsCell ProliferationHumansTumor MicroenvironmentCancer metastasismetastasisneuronal plasticityneurotrophic factorssynaptic transmissiontumor microenvironment

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.